A Phase 1 interventional study of ONO-3310 and Placebo in Type2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Renal Insufficiency, Chronic with a site in Japan — 13 open to participants now, 21 under way, 12 of them phase 3. Renal Insufficiency, Chronic · Japan.
Among the 102 studies in Renal Insufficiency, Chronic with a site in Japan, this one is the 58th largest by planned enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 10 of the 20 other live ones, and was the 98th registered.
3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →13 of the 102 studies in Renal Insufficiency, Chronic with a site in Japan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Japan, United States, Argentina and 24 more countries
Ages 18–99
Eli Lilly and Company · Sites in Japan, United States, Argentina and 1 more country
Ages 18+
AstraZeneca · Sites in Japan, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, United States, China and 5 more countries
Ages 2–18
Eli Lilly and Company · Sites in Japan, Argentina, Australia and 35 more countries
Ages 50+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 246 (57%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 73 across 2,163 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 216 across the 88 interventional studies, 2,000 across the 14 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 102 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
8 of the studies in Renal Insufficiency, Chronic with a site in Japan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07063316Boehringer IngelheimSGLT2 Inhibitors and Renal Anemia in Japan: RWD | 2026-12-25 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06527846Boehringer IngelheimPost Marketing Surveillance of JARDIANCE in Chronic Kidney Disease | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 102 studies in Renal Insufficiency, Chronic with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus
To investigate the safety, tolerability, and pharmacokinetics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects. In addition, in chronic kidney disease patients with type 2 diabetes mellitus, to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy adult part
Chronic kidney disease patient part
Exclusion Criteria:
Healthy adult part
Chronic kidney disease patient part
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-3310
Drug: Placebo
Drug: ONO-3310
Drug: Placebo
Drug: ONO-3310
Single oral dose of ONO-3310 to HV
Single oral dose of Placebo to HV
Multiple oral dose of ONO-3310 to HV
Multiple oral dose of Placebo to HV
Single or multiple oral dose of ONO-3310 to CKD patients
Adverse event
Number of participants with adverse events
Time frame: Through study completion, typically 10days (HV single), 23 days (HV multiple), and 74 days (CKD)
Maximum plasma observed concentration (Cmax)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Time to reach maximum observed concentration (Tmax)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24h)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Area under the plasma concentration versus time curve from time zero to infinity (AUCinf)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Area under the plasma concentration versus time curve from time zero to time of last measurable concentration (AUClast)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Elimination half-life (T1/2)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Apparent total clearance (CL/F)
Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
Urinary excretion rate of unchanged drug
Time frame: Up to 6 days (HV single)
Pharmacodynamics (evaluation of Urinary albumin-to-creatinine ratio)
Time frame: Up to 74 days (CKD)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Nov 2027, 17 months after the start.
Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 17 months is above that.
Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Ono Pharmaceutical Co., Ltd. →